Shares of Merck KGaA (OTCMKTS:MKGAF - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $168.61 and traded as high as $178.15. Merck KGaA shares last traded at $176.81, with a volume of 617 shares.
Merck KGaA Trading Up 1.5 %
The firm has a market capitalization of $22.85 billion, a price-to-earnings ratio of 21.25 and a beta of 0.93. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.99 and a current ratio of 1.56. The business has a fifty day moving average price of $168.61 and a 200 day moving average price of $163.88.
Merck KGaA (OTCMKTS:MKGAF - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported $1.99 EPS for the quarter, missing analysts' consensus estimates of $2.15 by ($0.16). The firm had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.58 billion. Merck KGaA had a return on equity of 12.14% and a net margin of 13.47%. As a group, equities analysts forecast that Merck KGaA will post 9.34 earnings per share for the current year.
Merck KGaA Company Profile
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
See Also
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
